InflaRx jumps on FDA 'Fast Track' tag for skin ulcer treatment

Inflarx NV

06/07/2022 13:14

** U.S.-listed shares of German biopharmaceutical company
InflaRx  IFRX.O  rise ~13% premarket
    ** IFRX receives "Fast Track" designation from FDA for
vilobelimab, its treatment for ulcerative pyoderma gangrenosum
(PG) urn:newsml:reuters.com:*:nGNX2SBB41
    ** PG is a rare condition that causes skin ulcers 
    ** Co previously received "orphan drug" designation for
vilobelimab for the treatment of PG from the FDA and Europe's
EMA
    ** Vilobelimab is also in development as a treatment for
cutaneous squamous cell carcinoma, a non-melanoma skin cancer 
    ** As of last close, IFRX shares down 70.17% YTD


 (Reporting by Raghavi Kasa in Bengaluru)
 ((Raghavi.Kasa@thomsonreuters.com;))